This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ZBTB7B / Zinc finger and BTB domain-containing protein 7B · IHC design guide
Design Immunohistochemistry for ZBTB7B
Plan chromogenic paraffin IHC around the predominantly nuclear ZBTB7B pattern, with bone marrow hematopoietic cells and adipocytes as high-staining and undetected comparators (HPA tissue IHC). Catalog antibody M06831 lists a human IHC dilution of 1:200–1:1000 (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ZBTB7B Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Predominantly nuclear staining (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in most tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining shows low consistency with RNA data (HPA tissue IHC) | |
| Regulation | Low tissue specificity at RNA level (HPA tissue RNA) | |
| Isoform / epitope | Two isoforms; epitope coverage is unclear (UniProt) |
Section 1
Recommended ZBTB7B IHC & IF Protocols
The catalog antibody’s IHC-P protocol is followed by two published ZBTB7B IHC methods (PMC12686175; PMC9235105).
| Sample | Paraffin-embedded Human Breast tissues; fixative not specified (datasheet M06831) |
| Fixation | Image fixative and duration unreported (datasheet M06831); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Mouse monoclonal (clone 7C12) anti-ZBTB7B, 1:200-1:1000 (datasheet M06831) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ZBTB7B-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule; UniProt: nuclear localisation).
Section 2
What Is the Expected ZBTB7B Staining Pattern?
ZBTB7B is a nuclear protein with no transmembrane segment (UniProt O15156 topology; UniProt O15156 subcellular location). In paraffin section IHC, expect nuclear staining in selected cells across many tissues, including glandular cells in colon and hematopoietic cells in bone marrow (HPA: nuclear expression in most tissues; HPA: High in colon glandular cells and bone marrow hematopoietic cells). Interpret tissue comparisons cautiously: HPA rates tissue IHC Enhanced but reports low consistency with RNA data and pending external verification (HPA tissue IHC reliability).
| Distinct nuclear chromogen in colon glandular cells or bone marrow hematopoietic cells, with nuclei identifiable on the counterstain (HPA: High in both cell populations). | This matches the reported compartment and positive cell populations (UniProt O15156: nucleus; HPA: nuclear expression in most tissues). Compare signal with a negative control before calling a sample positive (general IHC practice); the HPA tissue pattern awaits external verification (HPA tissue IHC reliability). |
| Predominantly cytoplasmic, membrane rim, or extracellular color while nuclei remain clear. | Those compartments conflict with the reported nuclear location and absence of a transmembrane segment (UniProt O15156 topology and subcellular location; HPA: nuclear expression). Review counterstain alignment and the negative control; a strong wrong-compartment signal warrants investigation as possible nonspecific staining (general IHC practice). |
| Strong color in hepatocytes, adipocytes, or glomerular cells, especially without nuclear restriction. | HPA reports ZBTB7B as Not detected in these respective cell populations (HPA: liver, adipose tissue, kidney). Check the cell identification and compare a negative control for antibody cross-reactivity or endogenous chromogenic activity (general IHC practice). A single unexpected sample does not by itself establish target expression. |
| Even haze across nuclei, cytoplasm, and empty slide areas obscures tissue boundaries. | A field-wide deposit does not resemble the reported nuclear pattern (HPA: nuclear expression in most tissues). Inspect the negative control and review blocking, washes, detection reagent, and chromogen development as general IHC background checks (general IHC practice); do not score the haze as ZBTB7B-positive cells. |
| No nuclear signal in a colon section's glandular cells or bone marrow section's hematopoietic cells. | This conflicts with HPA's High observations in those populations (HPA: colon; HPA: bone marrow), but tissue IHC has low consistency with RNA and awaits external verification (HPA tissue IHC reliability). Confirm that the intended cells are present, then check assay controls and routine IHC processing (general IHC practice). |
💡Expected ZBTB7B appearanceCall a convincing positive result when identifiable colon glandular or bone marrow hematopoietic cells show clear nuclear chromogen at the reported High level (HPA: colon; HPA: bone marrow; HPA: nuclear expression); diffuse field color or predominantly cytoplasmic or membrane staining is inconsistent with the reported compartment (HPA: nuclear expression; UniProt O15156 topology).
| Subcellular location and topology | ZBTB7B is nuclear and has no transmembrane segment (UniProt O15156). Score chromogen against the counterstained nuclei; a membrane pattern lacks support from the supplied localisation evidence (UniProt O15156; HPA: nuclear expression in most tissues). |
| Cell population within a tissue | High staining is reported for colon glandular cells and cerebellar Purkinje cells, while glial cells in caudate and hepatocytes are Not detected (HPA tissue IHC). Identify the specific cell population before assigning a tissue-wide result; HPA's entries do not make every cell in a positive tissue positive. |
| Interpretive confidence | Two rabbit polyclonal antibodies, HPA006811 and HPA025820, have IHC Enhanced status (HPA antibodies). The tissue profile still has low consistency between antibody staining and RNA data and is pending external verification (HPA tissue IHC reliability). Treat a matching stain as supportive evidence, not independent confirmation of specificity. |
| Isoforms and modifications | UniProt lists two isoforms and five modified residues, including phosphorylation and acetylation (UniProt O15156). The supplied records give no antibody epitope or isoform selectivity, so they cannot predict which isoform or modification a nuclear IHC signal represents. |
| Negative reference cells | Adipocytes, cardiomyocytes, and hepatocytes are reported Not detected in their listed tissues (HPA: adipose tissue, heart muscle, liver). These observations can help flag unexpected staining, but HPA's low antibody–RNA consistency limits their use as definitive biological negatives (HPA tissue IHC reliability). |
| IF/ICC Q&A: Where should signal appear? | In ICC-IF, HPA reports enhanced nucleoplasmic localisation and lists images from A-431, U-251MG, and U2OS (HPA subcellular; HPA antibodies: ICC Enhanced). This supports a nuclear interpretation for IF/ICC; the supplied record provides no IF/ICC protocol or dilution. |
| Situation | Likely cause | Next action |
|---|---|---|
| Positive tissue has no visible nuclear chromogen. | The expected cells may be absent from the section, or the IHC run may have failed; HPA reports High staining only for specified populations (HPA: colon glandular cells; HPA: bone marrow hematopoietic cells). | Locate the specified cells on the counterstain and check a concurrent positive control, antibody application, retrieval step, and detection reagents (general IHC practice). Do not infer ZBTB7B-specific fixation sensitivity; none is supplied. |
| Signal is mainly cytoplasmic or outlines cell membranes. | The compartment disagrees with nuclear localisation and the lack of a transmembrane segment (UniProt O15156; HPA: nuclear expression). Nonspecific staining or cell-boundary misreading is possible (general IHC practice). | Compare nuclear counterstain alignment and a negative control, then assess whether signal persists after routine antibody and detection checks (general IHC practice). Avoid scoring the wrong-compartment color as a positive nuclear result. |
| Hepatocytes, cardiomyocytes, or adipocytes show convincing color. | Those cells are reported Not detected in the corresponding HPA tissue entries (HPA: liver, heart muscle, adipose tissue). Cross-reactivity or endogenous chromogenic activity is a possible technical explanation (general IHC practice). | Verify cell identity and nuclear restriction, inspect a negative control, and check endogenous-activity blocking used by the chromogenic assay (general IHC practice). Report the discrepancy alongside HPA's limited tissue-profile confidence (HPA tissue IHC reliability). |
| Diffuse color covers tissue and surrounding blank areas. | Field-wide background is inconsistent with a cell-associated nuclear pattern (HPA: nuclear expression in most tissues). Incomplete blocking, washing, or overdevelopment can raise general IHC background (general IHC practice). | Check the negative control and blank areas, then review routine blocking, washes, and chromogen development (general IHC practice). Reassess nuclei only after background is low enough to distinguish cells from deposit. |
| A faint, patchy nuclear pattern is difficult to score. | Expression differs by cell population: HPA reports High in colon glandular cells but Low in lymph node germinal center cells (HPA tissue IHC). Variable cellular composition can complicate interpretation (general IHC practice). | Score the identified population and compartment, compare it with the same-run controls, and record heterogeneity without upgrading faint cells to High (general IHC practice; HPA: population-specific levels). |
| Two stained sections disagree about which cells are positive. | The HPA tissue profile has low antibody–RNA consistency despite IHC Enhanced antibody status (HPA tissue IHC reliability; HPA antibodies). Differences in section composition or assay performance also merit review (general IHC practice). | Match the same cell populations and nuclear scoring criteria, review controls and processing records, and describe the disagreement explicitly (general IHC practice). Avoid treating either section alone as external verification of the HPA pattern. |
Experiment evidence
IHC & IF images showing ZBTB7B staining
M06831 · IHCImmunohistochemistry validation of ZBTB7B using Anti-TH-POK ZBTB7B Monoclonal Antibody (M06831). Immunohistochemistry (IHC) analysis of para
M06831 · IFImmunofluorescent staining data of ZBTB7B using Anti-TH-POK ZBTB7B Monoclonal Antibody (M06831). Immunofluorescence (IF) analysis of HeLa ce
A06831 · IFFluorescent confocal image of Hela cell stained with ZBTB7B Antibody (C-term). Hela cells were fixed with 4% PFA (20 min), permeabilized wit
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000160685-ZBTB7B/tissue/cerebral+cortex#imid_2641796
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000160685-ZBTB7B/tissue/colon#imid_2614082
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000160685-ZBTB7B/tissue/liver#imid_2614083
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000160685-ZBTB7B/tissue/kidney#imid_2614076
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA025820; green = ZBTB7B, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA025820; green = ZBTB7B, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ZBTB7B IHC & IF
🧪Run cerebellum first and score Purkinje-cell staining (HPA: High in Purkinje cells). Use heart muscle cardiomyocytes as the negative tissue (HPA: Not detected in cardiomyocytes); on the cerebellum slide, treat unstained neighboring cells as a background reference, without assuming they are ZBTB7B-negative because HPA identifies only Purkinje cells in the supplied row (HPA: High in Purkinje cells).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ZBTB7B in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species, immunoglobulin class, and monoclonal format; and, where available, a ZBTB7B-knockout specimen as a biological negative (standard IHC practice). Quench endogenous peroxidase and assess background in the hematopoietic cells if bone marrow is used as an additional positive tissue (HPA: High in bone marrow hematopoietic cells; standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported in the supplied evidence; the selected M06831 paraffin-section caption does not state its fixative (M06831 tissue-IHC caption: fixative unreported). Antigen-retrieval dependence is unreported, so optimize retrieval on the positive and negative sections before scoring (standard IHC practice). The supplied evidence does not establish that frozen sections or IF are easier; if using cerebellum for IF, check autofluorescence before interpreting Purkinje-cell signal (HPA: High in Purkinje cells; standard IF practice).
HPA tissue IHC evidence for ZBTB7B
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Endothelial cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ZBTB7B IHC Tips
Troubleshoot ZBTB7B staining by checking nuclear localisation, cell identity, processing conditions and control sections (UniProt O15156: nucleus; HPA: nuclear expression in most tissues).
What retrieval should I use if nuclear ZBTB7B staining is weak?
Use Tris-EDTA at pH 9.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting: nuclear antigen). Let sections cool in buffer, then compare a retrieved section with a no-retrieval control under the same detection conditions (standard IHC practice). Judge improvement by sharper nuclear staining in the relevant cells, because ZBTB7B is nuclear and HPA reports nuclear expression in most tissues (UniProt O15156: nucleus; HPA: tissue IHC profile). If staining remains weak, test a milder citrate buffer at pH 6.0 as a fallback on adjacent sections, keeping the antibody and detection settings fixed (standard IHC practice).
How should I investigate weak staining after tissue fixation?
ZBTB7B-specific sensitivity to fixative type or fixation duration is unknown from the supplied evidence (selected M06831 caption: fixative not stated). The M06831 image uses paraffin-embedded human breast tissue, but its caption does not establish how that tissue was fixed (selected M06831 caption). Record fixative, fixation duration, processing batch and section age for each specimen; compare adjacent sections with the same pH 9.0, 20 min retrieval and detection run (page retrieval setting; standard IHC practice). If one batch stains poorly, include a section from a previously successful batch in the next run before attributing the difference to ZBTB7B biology (standard IHC practice).
How can I assess predominantly cytoplasmic staining?
Expect the interpretable signal to be nuclear: UniProt places ZBTB7B in the nucleus, and HPA describes nucleoplasmic localisation (UniProt O15156: subcellular location; HPA: subcellular). Review the chromogen against a light nuclear counterstain and score nuclear and cytoplasmic staining separately rather than combining them (standard IHC practice). If cytoplasmic staining dominates, compare serial sections processed with and without primary antibody, and check whether the signal tracks tissue folds or precipitate (standard IHC practice). ZBTB7B has no annotated transmembrane segment, so membrane outlining should prompt a specificity check, particularly if expected nuclear staining is absent (UniProt O15156: topology; standard IHC practice).
Could isoforms or epitope masking explain discordant sections?
ZBTB7B has 2 listed isoforms and a BTB domain spanning residues 34–115 (UniProt O15156: isoforms and domains). Its annotated modifications include phosphorylation and acetylation, but the supplied evidence does not identify the catalog antibody’s epitope or establish a modification-dependent IHC effect (UniProt O15156: modified residues; supplied product evidence). Check the antibody’s documented immunogen region before interpreting differential staining as isoform selection, and keep retrieval and detection identical across compared sections (standard IHC practice). If uncertainty remains, compare a second antibody with a documented, distinct epitope on adjacent sections; concordant nuclear patterns provide stronger support for antigen recognition (standard IHC practice; UniProt O15156: nucleus).
How can I compare this IHC pattern with multiplex IF?
Treat IF as a separate assay and first verify that the chosen antibody works under the intended IF fixation conditions (standard IF practice). Pair ZBTB7B with an independently validated marker for the cell population being assessed, then inspect nuclear colocalisation because its reported location is nuclear or nucleoplasmic (UniProt O15156: nucleus; HPA: subcellular). Choose fluorophores after examining an unstained section for autofluorescence, and include single-label controls to assess bleed-through (standard IF practice). For this non-membrane protein, use a mild permeabilisation step to admit antibody to the nuclear epitope, then compare it with a less-permeabilised control to detect lost morphology or diffuse background (UniProt O15156: topology and location; standard IF practice).
How do I separate nonspecific chromogen from ZBTB7B signal?
Compare the test section with a no-primary control on the same tissue and run, using the same chromogen development time (standard IHC practice). Diffuse deposit across nuclei and stroma, staining along folds, or signal concentrated at section edges should trigger a check of blocking, washing and chromogen development (standard IHC practice). If using peroxidase detection, include a peroxidase block and inspect the no-primary control for residual endogenous enzyme activity (standard IHC practice). Count only crisp nuclear staining in intact cells as candidate ZBTB7B signal, since UniProt places the protein in the nucleus and HPA reports predominantly nuclear tissue staining (UniProt O15156: nucleus; HPA: tissue IHC profile).
What is a defensible way to score ZBTB7B IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define cell populations and analysis regions before scoring, then count intact nuclei within comparable tissue area on every section (standard IHC practice). Report the percentage of positive nuclei and, if intensity is reproducible, an H-score calculated as 1 × % weak + 2 × % moderate + 3 × % strong nuclei (standard IHC scoring practice). For sparse populations, report positive nuclei per mm² alongside the total nuclei examined, and normalise comparisons to the same annotated cell population and viable area (standard IHC practice). Keep exposure, counterstain, chromogen development and thresholds consistent across batches; HPA notes low staining–RNA consistency and pending external verification (standard IHC practice; HPA: reliability description).
When should I regard a positive section as unconvincing?
A convincing pattern should favour nuclei in intact cells, consistent with UniProt’s nuclear assignment and HPA’s nuclear tissue profile (UniProt O15156: nucleus; HPA: tissue IHC profile). Check cell identity before comparing tissues: HPA lists high staining in appendix glandular cells but no detection in liver hepatocytes, and neither observation establishes a universal positive or negative control (HPA: tissue IHC). Discount staining restricted to section edges, necrotic regions or the no-primary control, and investigate any predominantly membrane or cytoplasmic pattern (standard IHC practice; UniProt O15156: nucleus and topology). Interpret unexpected patterns cautiously because HPA reports low agreement between staining and RNA data and says external verification is pending (HPA: reliability description).
Boster reagents
Best ZBTB7B / Zinc finger and BTB domain-containing protein 7B IHC Antibodies
Two human-reactive ZBTB7B antibodies have image data: paraffin-section IHC of human breast tissue (M06831 IHC caption) and IF of HeLa cells (A06831 IF caption).
Real IHC data
Anti-TH-POK ZBTB7B Monoclonal Antibody
Cat # M06831
Real IF data
Anti-ZBTB7B Antibody (C-term)
Cat # A06831
M06831 has an IHC image of paraffin-embedded human breast tissue with AEC staining (M06831 IHC caption). A06831 has a confocal IF image of HeLa cells (A06831 IF caption).
Which to pick: Choose mouse monoclonal M06831 for tissue IHC: its application list includes IHC, and its own image shows paraffin-embedded human breast tissue (M06831 catalog; M06831 IHC caption); the fixative is unreported (M06831 IHC caption). Choose rabbit polyclonal A06831 for IF/ICC in human cells: its application list includes IF, and its own image shows PFA-fixed HeLa cells (A06831 catalog; A06831 IF caption). Neither is documented for another species; both list Human reactivity only (M06831 catalog; A06831 catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O15156 (ZBT7B_HUMAN, Zinc finger and BTB domain-containing protein 7B).
- Human Protein Atlas. ZBTB7B tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ZBTB7B subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. ZBTB7B antibody validation summary (2 antibodies).
- Inhibition of ZBTB7B-mediated ADPGK transcription by NEDD4 impedes glycolysis and progression of lung adenocarcinoma. Oncogenesis 2026 — PMC13002864.
- ZBTB7B modulates the androgen receptor as an upstream regulator via colocalization and direct binding in LNCaP prostate cancer cells. Translational cancer research 2025 — PMC12686175.
- Epigenetic DNA methylation of Zbtb7b regulates the population of double-positive CD4(+)CD8(+) T cells in ulcerative colitis. Journal of translational medicine 2022 — PMC9235105.
- Super-enhancer profiling reveals ThPOK/ZBTB7B, a CD4(+) cell lineage commitment factor, as a master regulator that restricts breast cancer cells to a luminal non-migratory phenotype. Cellular and molecular life sciences : CMLS 2025 — PMC12615902.
- PubMed PMID:9370309 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ZBTB7B (Zinc finger and BTB domain-containing protein 7B). Expected localisation Predominantly nuclear staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: M06831 at 1:200-1:1000 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded Human Breast tissues; fixative not specified (datasheet M06831); 2. Fixation: Image fixative and duration unreported (datasheet M06831); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Mouse monoclonal (clone 7C12) anti-ZBTB7B, 1:200-1:1000 (datasheet M06831); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Antibody staining shows low consistency with RNA data (HPA tissue IHC); Isoform / epitope: Two isoforms; epitope coverage is unclear (UniProt); Regulation: Low tissue specificity at RNA level (HPA tissue RNA). Evidence: UniProt O15156, HPA tissue IHC · Enhanced, HPA ICC-IF · nucleoplasm., Datasheet M06831, PMC12686175, PMC9235105. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ZBTB7B/immunohistochemistry-ihc-guide.